To ensure that a patient's test is billed to their 2024 health benefits, testing must be started before the end of the year. For exome, genome, or Xpanded testing, if you do not expect parental samples to be received before the end of the year, please contact us at [email protected] to determine how to proceed.

Comprehensive Epilepsy Panel

New York
Approved

Genes

ADSL, ALDH5A1, ALDH7A1, ALG13, ANKRD11, ARG1, ARHGEF9, ARX, ASNS, ATP1A2, ATP1A3, ATP6AP2, ATRX, BRAT1, C12orf57, CACNA1A, CACNA1E, CACNA1G, CASK, CDKL5, CHD2, CHRNA2, CHRNA4, CHRNA7, CHRNB2, CLCN4, CLN3, CLN5, CLN6, CLN8, CNTNAP2, CSTB, CTSD, CTSF, CUL4B, DCX, DDX3X, DEPDC5, DNAJC5, DNM1, DOCK7, DYRK1A, EEF1A2, EHMT1, EPM2A, FGF12, FLNA, FOLR1, FOXG1, FRRS1L, GABBR2, GABRA1, GABRB2, GABRB3, GABRG2, GAMT, GATM, GLDC, GNAO1, GOSR2, GRIN1, GRIN2A, GRIN2B, HCN1, HNRNPU, IQSEC2, KANSL1, KCNA2, KCNB1, KCNC1, KCNH1, KCNJ10, KCNMA1, KCNQ2, KCNQ3, KCNT1, KCTD7, KDM6A, KIAA2022 (NEXMIF), LGI1, MAGI2, MBD5, MECP2, MEF2C, MFSD8, NALCN, NGLY1, NHLRC1, NPRL3, NR2F1, NRXN1, PACS1, PAFAH1B1, PCDH19, PHGDH, PIGA, PIGG, PIGN, PIGO, PIGT, PIGV, PLCB1, PNKP, PNPO, POLG, PPP2R5D, PPT1, PRRT2, PURA, QARS, SATB2, SCARB2, SCN1A, SCN1B, SCN2A, SCN8A, SHANK3, SLC13A5, SLC19A3, SLC25A22, SLC2A1, SLC35A2, SLC6A1, SLC6A8, SLC9A6, SMARCA2, SMC1A, SNAP25, SPATA5, SPTAN1, STX1B, STXBP1, SYNGAP1, SZT2, TBC1D24, TBL1XR1, TCF4, TPP1, TSC1, TSC2, TUBB2A, UBE3A, WDR45, WWOX

Conditions

  • KBG Syndrome
  • Cabezas syndrome
  • Creatine Deficiency Syndromes
  • Early-Onset Epileptic Encephalopathy and/or Infantile Spasms
  • Epilepsy and Mental Retardation Limited to Females
  • Epilepsy with Variable Learning and Behavioral Disorders
  • Generalized Epilepsy with Febrile Seizures Plus (GEFS+)
  • Adenylosuccinate Lyase Deficiency
  • Glucose Transporter Type I Deficiency Syndrome
  • Alpers syndrome (Alpers-Huttenlocher syndrome)
  • Lafora Disease
  • Lissencephaly
  • Microcephaly with Early-Onset Intractable Seizures and Developmental Delay (MCSZ)
  • Angelman syndrome (AS)
  • Neuronal Ceroid Lipofuscinoses (NCL)
  • Arginase Deficiency
  • Ohtahara Syndrome
  • Progressive Myoclonic Epilepsy
  • Pyridoxine Dependent Seizures
  • Rett syndrome
  • Atypical Rett Syndrome
  • Unverricht-Lundborg Disease (Baltic Myoclonus)
  • West Syndrome
  • Benign Familial Neonatal-Infantile Seizures (BFNIS)
  • Benign Familial Neonatal Seizures (BFNS)

Clinical Utility

  • Molecular confirmation of a clinical diagnosis
  • To assist with decisions about treatment and management of individuals with epilepsy
  • Testing of at-risk relatives for specific known mutation(s) previously identified in an affected family member

Lab Method

  • Next-Gen Sequencing
  • Deletion/Duplication Analysis

The American Epilepsy Society has endorsed an evidence-based practice guideline supporting exome or genome sequencing as a first-tier test for patients with unexplained epilepsy.

References:

  1. Smith, L., Malinowski, J., Ceulemans, S., Peck, K., Walton, N., Sheidley, B. R., & Lippa, N. (2023). Genetic testing and counseling for the unexplained epilepsies: An evidence-based practice guideline of the National Society of Genetic Counselors. Journal of Genetic Counseling, 32, 266– 280. https://doi.org/10.1002/jgc4.1646

Test Code

523

CPT Codes*

81403x2, 81404x2, 81405x3, 81406x4, 81407x1, 81479x3, 81185x1, 81189x1, 81302x1, 81304x1

ABN Required

No

Turnaround Time**

4 weeks

Preferred Specimen

2-5 mL Blood - Lavender Top Tube

Alternative Specimen

Buccal Swabs

*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

**Turnaround times are estimates and begin once the sample(s) begin processing at the GeneDx lab and could be extended in situations outside GeneDx’s control.

Need something else?

Search More Tests